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Abstract
Background: The ras genes play an important role in the development and progression of human tumours.
Neutralizing Ras proteins in the cytoplasm could be an effective approach to blocking ras signalling. In this study,
we prepared anti-p21Ras single chain fragment variable antibody (scFv) and investigated its immunoreactivity with
human tumours.
Methods: The coding sequences of H-ras, K-ras, and N-ras were separately ligated into the vector pET-28a(+).
Then, recombinant expressing plasmids were induced by IPTG for p21Ras expression in E. coli. Hybridoma cell lines
producing anti-p21Ras monoclonal antibodies were isolated using wildtype p21Ras proteins as immunogens. Anti-
p21Ras scFv antibody was prepared from the hybridoma by the phage scFv display method. The immunoreactivity
of the anti-p21Ras monoclonal antibody and the scFv antibody was identified by ELISA and immunocytochemistry.
Results: We prokaryotically expressed wildtype H-p21Ras, K-p21Ras and N-p21Ras and generated the hybridoma
cell line KGH-R1, producing anti-p21Ras monoclonal antibodies. It was demonstrated that KGH-R1 monoclonal
antibody could recognize wildtype and mutated H-p21Ras, K-p21Ras and N-p21Ras in human tumour cell lines.
In all 14 types of primary human cancer tissues tested, the monoclonal antibody presented strong immunoreactivity
but showed weak or negative immunoreactivity in the corresponding normal tissues. Subsequently, we prepared
anti-p21Ras scFv from hybridoma KGH-R1, which showed the same immunoreactivity as the original
monoclonal antibody. Sequence analysis demonstrated that the nucleotides and amino acids of the scFv exhibited
an approximately 50 % difference from the anti-p21Ras scFv reported previously.
Conclusions: This study presents a novel anti-p21Ras scFv antibody. Our data suggest that the scFv may be useful for
ras signalling blockage and may be a potential therapeutic antibody for ras-derived tumours.
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Background
Because of the important role of ras in carcinogenesis and
progression, the ras signalling pathway has attracted con-
siderable attention as a target for anticancer therapy. The
ras gene product, p21Ras, is a monomeric membrane-
localized G protein of 21 kD, which functions as a molecu-
lar switch converting signals from the cell membrane to the
nucleus and linking receptor and nonreceptor tyrosine
kinase activation to downstream cytoplasmic or nuclear
events. The biological effects of p21Ras depend on its bio-
chemical properties of being a small GTP-binding protein
and on its correct cellular location at the cytoplasmic face
of the plasma membrane [1]. Thus, the neutralization of
p21Ras proteins in the cytoplasm using specific antibodies
may block ras signalling and constitute a promising thera-
peutic strategy [2].
It is well known that whole antibodies can penetrate
cells only with difficulty due to their large molecular size.
In recent years, a series of low-molecular-weight anti-
bodies containing antigen-binding domains have been
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explored to develop antibody-based drugs with better
tumour penetration, such as antigen-binding fragment [3],
single chain fragment variable (scFv) [4], and single-domain
antibodies [5]. It has been found that scFv antibodies pene-
trate the cell membrane better than whole antibodies [6, 7]
and result in no immunological rejections due to lacking
the Fc fragment [8, 9], giving them advantages as intracellu-
lar immunization and therapeutic antibodies. Currently,
scFv antibodies have been applied in many fields, including
anti-viral and cancer therapy [10–12].
Both overexpression and mutation can activate ras
genes. The overexpression of p21Ras has been detected
in many human tumours [13–17]. The overexpression of
ras family members led to the acquired resistance of
cancer to cetuximab treatment [18]. It has been found
that ras mutations are present in approximately 33 % of
all human tumours [19]. K-ras mutations occur fre-
quently in non-small-cell lung, colorectal, and pancreatic
carcinomas; H-ras mutations are common in bladder,
kidney, and thyroid carcinomas; and N-ras mutations
are found in melanoma, hepatocellular carcinoma, and
haematologic malignancies [20]. However, previously re-
ported anti-p21Ras antibodies were derived from mutated
p21Ras antigen [21–23]. In this study, we isolated hybrid-
oma cell lines producing anti-p21Ras monoclonal anti-
bodies, using wildtype p21Ras proteins as immunogens,
prepared anti-p21Ras scFv antibodies from the hybrid-
omas, and then investigated their immunoreactivity with
human tumour cell lines and primary tumour tissues.
Methods
Preparation of the wildtype p21Ras proteins
The coding sequences (CDS) of the H-ras, K-ras, and N-
ras genes were chemically synthetized according to their
wildtype mRNA sequences published in NCBI GenBank:
NM_005343 for H-ras, M54968 for K-ras, and
BC005219 for N-ras. The restriction enzyme Bam HI
cutting site GGATCC was ligated at the 5′ end of the
CDS, and the Hind III cutting site AAGCTT was ligated
at the 3′ end during synthesis. After digestion with Bam
HI and Hind III, the three CDS fragments were ligated
separately into the vector pET-28a(+) by T4 ligase. Then,
recombinant expressing plasmids were transformed into
E. coli BL21(DE3) and screened by kanamycin, induced
by IPTG for p21Ras expression [24]. Expressed p21Ras
proteins were purified by Ni2+-NTA resin with the mild
denaturant urea and then underwent SDS-PAGE ana-
lysis, followed by dialysis for renaturation.
Preparation of hybridomas producing broad-spectrum
anti-p21 Ras mAb
Balb/c mice were immunized by injection with wildtype
H-p21Ras expressed prokaryotically. The mouse splenic
B lymphocytes were fused with myeloma cell lines SP2/
0. After selective culture using HAT selective culture
medium, the fused hybridoma cells were screened by an in-
direct ELISA method with all three wildtype p21Ras pro-
teins and then cloned and subcloned to obtain hybridoma
cell lines producing monoclonal antibodies against wildtype
H-p21Ras, K-p21Ras and N-p21Ras. All hybridoma cell
lines were subcloned twice. Finally, the hybridoma cell lines
were injected into the peritoneal cavity of Balb/c mice to
produce monoclonal antibodies [21]. A completed ARRIVE
guidelines checklist is included in Additional file 1. Human
cancer cell lines were used to identify the immunoreactivity
of the monoclonal antibodies by Western blot. Primary
tumour tissues and their corresponding normal tissues were
employed to investigate the tumour reactivities of the
monoclonal antibodies by immunohistochemical staining,
and the results were described by HSCOREs [25].
Construction of scFv phage display library
Hybridoma cell line KGH-R1, which produced excellent
broad-spectrum anti-p21Ras mAb, was used to con-
struct a phage scFv display library. Total RNA was iso-
lated from KGH-R1 cells using RNAiso plus (MrcGene)
and reverse transcribed to cDNA using the RevertAid™
H Minus First Strand cDNA Synthesis Kit (Fermentas).
The heavy chain variable region (VH) and light chain
variable region (VL) were amplified using primers pro-
vided by the Recombinant Phage Antibody System (GE
Healthcare, RPAS). A DNA linker complementary to the
3′ end of VH and 5′ end of VL was ligated between the
VH and VL fragments by overlapping extended PCR
amplification to construct the scFv gene.
The phage scFv display library was constructed accord-
ing to the RPAS system manual (GE Healthcare). Briefly,
the scFv fragment genes and the phagemid pCANTAB-5E
were sequentially digested with the Sfi I and Not I restric-
tion enzymes. After purification by agarose gel extraction,
both the scFvs fragments and the pCANTAB-5E vector
with Sfi I and Not were ligated using T4 DNA ligase,
transformed into competent E. coli TG1 cells, and cul-
tured on SOBAG plates (SOB-AG, containing 100 μg/ml
ampicillin and 2 % glucose) at 37 °C. All of the bacterial
single colonies that grew on the SOBAG plate were col-
lected, mixed and cultured in 2 × YTAG medium. The
helper phage M13K07 at 1011 pfu was added to the collec-
tions and co-cultured at 30 °C for 1 h to obtain recombin-
ant phages expressing the scFv antibodies and g3p fusion
proteins on the surface. The scFv phages were purified
and concentrated by polyethylene glycol (20 % PEG8000,
2.5 mol/L NaCl). The pellet was resuspended in PBS to
obtain the phage scFv display library.
Enrichment of scFv phage
The phage scFv display library underwent three rounds
of panning using H-p21Ras, K-p21Ras and N-p21Ras
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protein antigens, respectively. Briefly, the flask was coated
with p21Ras protein dissolved in 0.1 mM NaHCO3. After
blocking with BSA, the library was added to the flask and
incubated at 37 °C for 2 h, followed by washing with PBST
(containing 0.05 % tween-20, pH 7.4) 10 times, followed
by washing PBS (without Tween-20) an additional 10
times to remove unbound phage particles. Specifically
bound phages were eluted with 0.1 M HCL/glycine
(containing 0.1 % BSA, pH 2.2). The eluent was neu-
tralized with pH 9.0 Tris/HCl, was used to infect
TG1 cells and was then rescued with helper phage
M13K07. These enriched scFv phages were used in
the next round of panning [26, 27]. In each panning
round, the numbers of input and output phages were
counted using the double agar layer method.
Identification of scFv-phages
E. coli TG1 cells were infected by the final enriched phage
pools and cultured on an SOB-AG plate. Single colonies
were picked and rescued individually with M13K07 in 96-
well plates. The phages from individual wells were assayed
by ELISA to detect their specific antigen binding activities,
utilizing p21Ras proteins as antigens, scFv-phage as pri-
mary antibody, and HRP-conjugated mouse anti-M13
mAb as second antibody. The positive phages were further
identified by Sfi I and Not I enzyme digestion and PCR
amplification with pCANTAB-5E primers (forward,
S1: 5-CAACGTGAAAAAATTATTATTCGC-3; reverse,
S6: 5-GTAAATGAATTTTC TGTATGAGG-3). The amp-
lified products were ligated into a pMD18-T vector for se-
quence analysis.
Bioinformatics analysis of scFv gene and 3D modelling
The sequence of the scFv gene was blasted with known
murine genes for homology analysis in the GenBank
database, as described previously [28]. The amino acid
residues, CDRs and FRs were determined according to
the IMGT numbering system and Kabat by IgBLAST
[28]. The 3D structure of scFv antibody was generated
by SWISS-MODEL [29, 30].
Expression of soluble scFv antibodies
The expression of soluble scFv antibodies was performed
according to the manual and reference [31]. Briefly, the
p21Ras-positve phages were used to infect HB2151 cells
and cultured in plates. A single colony was picked and
grown overnight to express soluble anti-p21Ras scFv
antibodies with E-tag peptide at the end through the
induction of IPTG. The soluble scFv antibodies were




Human tumour cell lines harbouring wildtype or mutated
Ras [32, 33], primary tumour tissues and the corresponding
normal tissues were employed to detect the immunoreac-
tivities of the scFv antibodies by immunohistochemical
staining. The soluble scFv antibodies were used as the pri-
mary antibody, whereas Anti-E-tag monoclonal antibody
conjugated with HRP served as the second antibody to bind
E-tag protein ligated to the end of the scFv antibody. The
scFv immunoreactivity with p21Ras was further detected
by Western blot in the tumour cell lines MDA-MB-435,
MDA-MB-231 and SKOV3 (ATCC USA) and the normal
cell line KMB17 (normal human embryonic diploid lung
fibroblast cell, constructed by the Institute of Medical
Biology, Chinese Academy of Medical Sciences). β-actin
was used as a control, with anti-β-actin monoclonal anti-
body conjugated with HRP.
Ethics statement
This study including animal work has the approval of the
Ethics Board of Kunming General Hospital and is also in
accordance with the Helsinki Declaration of 1975. Written
informed consent was obtained from every patient. All
human tissues were processed anonymously.
Results
Preparation of hybridomas and anti-p21Ras monoclonal
antibodies
By cloning the CDS of the H-ras, K-ras, N-ras genes into
pET-28(+) vectors, we constructed a prokaryotically
expressive vector (Fig. 1a, b) that effectively expressed H-
p21Ras, K-p21Ras and N-p21Ras protein in E. coli BL21.
SDS-PAGE analysis showed that the apparent molecular
weight of the three p21Ras proteins was 25 KD (Fig. 1c).
The purity of p21Ras protein was more than 95 %.
H-p21Ras was used as an immunogen to immunize
BALB/c mice to isolate hybridomas. To achieve mono-
clonal antibodies that simultaneously recognized H-
p21Ras, K-p21Ras and N-p21Ras, the three p21Ras were
used as antigens to screen the hybridomas in an ELISA
assay. In total, we obtained 13 hybridomas that pro-
duced monoclonal antibodies against the three different
p21Ras proteins. Karyotype analysis showed that the me-
dian chromosome numbers of the 13 hybridomas were
97–100. Immunochromatography indicated that the
monoclonal antibodies produced by all 13 hybridomas
were of the IgG2b/κ subtype. Monoclonal antibodies in
ascites reached a high titre of 1:128000. The immunoreac-
tivities of the monoclonal antibody KGH-R1 were deter-
mined by Western blot and immunohistochemistry. The
KGH-R1 monoclonal antibody demonstrated positive im-
munoreactivities in all 13 human solid tumour cell lines
and 2/6 leukaemia cell lines (Table 1). In all 14 types of
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primary human cancer tissues tested here, the monoclonal
antibody presented strong immunoreactivity but showed
weak or negative immunoreactivity in the corresponding
normal tissues (Table 2, Fig. 1d).
Construction and panning of scFv phage display library
The scFv gene consists of a heavy chain variable region
(VH) and a light chain variable region (VL), joined by a
neutral linker (Fig. 2a). We amplified VH (340 bp) and
VL (320 bp) from the cDNA of the KGH-R1 hybridoma.
Then, we connected both to DNA linker by overlapping
extended PCR to construct a 750 bp scFv gene (Fig. 2b).
The scFv gene repertoire was ligated to the phagemid
pCANTAB 5E and then transformed into competent
TG1 cells and grown in SOBAG plates, obtaining 1 × 107
TG1 colonies transformed by the recombinant phage
plasmids (Fig. 2c). We collected all of the TG1 colonies,
co-cultured them with M13KO7 helper phages, and
established the scFv phage display library, in which scFv-
g3p fusion proteins were expressed at the tips of the
phages. To obtain phages expressing anti-p21Ras scFv
antibodies from the library, the library was selected and
panned using the H-p21Ras, K-p21Ras, and N-p21Ras
proteins, in turn. After three rounds of panning, the eluted
phages were maintained at 1 × 106 pFU/mL, and the
number of input phage pools was maintained at 1 × 109
pFU/mL (Fig. 2d).
Characteristics of anti-p21Ras scFv antibodies
To obtain monoclonal phages expressing anti-p21Ras
scFv antibodies, we infected TG1 cells with the enriched
scFv phage pool and plated them on SOBAG plates.
Then, 40 colonies were rescued by M13K07. Indirect
ELISA tests showed that all 40 colonies expressed scFv
antibodies that could bind H-p21Ras, K-p21Ras and N-
p21Ras simultaneously. Recombinant phagemids were iso-
lated from each of the 40 colonies and digested by Sfi I
and Not I and then ligated with pMD18-T vector for DNA
sequencing. Sequence analysis demonstrated that the se-
quences of the 40 colonies were the same. The number of
amino acids and complementary determining regions
(CDRs) of the VH and VL domains were determined using
Fig. 1 Wildtype p21Ras proteins and anti-p21Ras monoclonal antibodies. a The plasmid map of recombinant pET-28a(+) vector expressing H-ras,
in which H-ras gene CDS with Bam HI and Hind III restriction enzyme sites was cloned into a pET-28a(+) vector with a histidine tag-compatible
end. b The three recombinant pET28a(+) plasmids were digested into two fragments by Bam HI and Hind III, the 570 bp of the ras gene CDS and
5340 bp of the pET-28a(+) vector. c SDS–PAGE analysis showed that the molecular weight of the three p21Ras proteins with His tag was 25 kDa.
d KGH-R1 monoclonal antibody against three p21Ras proteins demonstrated strong immunoreactivity to cancer tissues but negative immunoreactivity
to corresponding normal tissues
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IgBLAST. KGHR1-scFv had 738 nucleotides encoding 246
amino acids, of which VH consisted of 117 amino acids,
VL consisted of 114 amino acids, and the flexible amino
acid linker consisted of 15 amino acids. Both the VH and
VL fragments had 3 CDR regions and 4 FR regions (Fig 3a).
Homology analysis revealed that VH belongs to murine
subfamily III and that VL belongs to the subfamily VII κ
chains. We constructed a three-dimensional model of the
scFv antibody by the SWISS MODEL method. In the 3D
model, scFv consists of the VH chain and the VL chain
connected by a polypeptide linker chain (Fig. 3b).
Immunoreactivity of soluble anti-p21Ras scFv antibodies
Soluble anti-p21Ras scFv antibodies were prepared by
infecting the non-amber suppressor E. coli strain
HB2151 with the recombinant phages. The Western blot
assay showed that anti-p21Ras scFv antibody could spe-
cifically bind the p21Ras protein in the tested cells
(Fig. 3c). We further evaluated the immunoreactivities of
scFv in human tumour cell lines, primary solid tumour
tissues and normal tissues by immunohistochemical
staining. The results demonstrated that the soluble scFv
displayed strong immunostaining in all the human
tumour cell lines and all types of primary human cancer
tissues tested here. However, all of the corresponding
normal tissues showed negative immunostaining. The
granular positive signal was mainly located in the cyto-
plasm and membrane (Table 3, Fig. 3d). The results indi-
cated that the obtained scFv could recognize the p21Ras
antigen epitope in tumour cells.
Discussion
Antibody-based drugs are promising agents for cancer
therapy. In recent years, certain antibody drugs have
been clinically approved and used frequently in cancer
treatment. Trastuzumab, a chimeric monoclonal anti-
body against Her2 protein, is the most impressive target
drug for breast cancer therapy [34, 35]. Rituximab, an
anti-CD20 monoclonal antibody, is another of the most
effective drugs in B cell malignant lymphoma treatment
[36]. The gene ras is a well-known and important onco-
gene involved in the development and progression of
many human tumours, but no antibody drugs targeting
the ras gene have been applied clinically. The main rea-
son is that the intracellular location of p21Ras has lim-
ited the effects of antibodies because intact antibodies
can not penetrate the cell membrane. Thus, small mo-
lecular antibodies, such as scFv, are proposed to treat
ras-derived tumours.
Because hybridoma cell lines are the most important
resources for scFv [37–39], we established anti-p21Ras
hybridomas using prokaryotically expressed wildtype H-
p21Ras protein as an immunogen. H-p21Ras, K-p21Ras
and N-p21Ras were used to screen the hybridoma clones.
Table 2 Immunoreactivity of KGH-R1 mAb in human tumours
and corresponding normal tissues




Colorectal cancer 30 208.69 ± 84.40 6.88 ± 1.53
Gastric cancer 30 155.29 ± 87.50 7.86 ± 2.79
Oesophageal cancer 30 163.73 ± 66.00 8.50 ± 3.28
Bladder cancer 30 146.76 ± 95.36 8.10 ± 2.43
Lung adenocarcinoma 30 238.63 ± 72.00 7.00 ± 1.77
Lung squamous cell carcinoma 30 178.26 ± 83.99 7.00 ± 1.77
Lung small cell carcinoma 30 134.38 ± 91.58 7.00 ± 1.77
Papillary thyroid carcinoma 30 239.33 ± 75.51 8.43 ± 2.32
Hepatocarcinoma 30 184.38 ± 96.75 11.29 ± 5.51
Prostate carcinoma 30 114.77 ± 70.59 13.00 ± 4.24
Breast cancer 30 197.46 ± 56.33 9.23 ± 3.19
Endometrial cancer 30 139.29 ± 86.00 15.75 ± 5.72
Glioma 30 97.60 ± 8.85 17.30 ± 8.32
Renal cell carcinoma 30 117.50 ± 73.86 16.00 ± 5.85
aMean ± SD
Table 1 Immunoreactivity of KGH-R1 mAb in human tumour
cell lines
Tumour cell linesa Ras statusb Western blot Immunocytochemistry
QGY7703 Unknown + +
SMMC7721 Unknown + +
HepG2 N, mutant + +
BGC823 Unknown + +
MKN28 Unknown + +
HCT116 K, mutant + +
T24 H, mutant + +
SKOV3 Unknown + +
MDA-MB-231 K, mutant + +
MDA-MB-435 Unknown + +
MCF7 Unknown + +
HeLa Wildtype + +
Hep2 Unknown + +
C8166 Unknown + +
K562 Unknown + +
Daud I Unknown - -
HL60 N, mutant - -
MT4 Unknown - -
THP1 N, mutant - -
aQGY7703, SMMC7721, HepG2: hepatocarcinoma; BGC853, MKN28: gastric
cancer; HCT116: colorectal cancer; T24: bladder cancer; SKOV3: ovary cancer;
MDA-MB-231, MDA-MB-435, MCF7: breast cancer; HeLa: cervical cancer; Hep2:
laryngocarcinoma; C8166, K562, Daud I, HL60, MT4, THP1: leukaemia.
bpublished data
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Finally, the hybridoma KGH-R1, producing a broad-
spectrum monoclonal antibody against the three p21Ras
proteins, was isolated. Interestingly, the monoclonal
antibodies reacted with both wildtype and mutated
p21Ras in human tumour cell lines and presented excel-
lent immunoreactivities with the majority of human
tumour cell lines and primary tumour tissues but nega-
tive immunostaining in the corresponding normal tis-
sues. The characteristics mentioned above give these
antibodies important value as therapeutic prodrugs. To
our knowledge, this study is the first to use wildtype p21
Ras as an immunogen to prepare monoclonal antibodies.
The anti-p21Ras monoclonal antibodies reported previ-
ously were derived from mutated p21Ras, of which Y13-
259 and Y13-238 were generated using p21 protein
encoded by the v-ras gene of the Harvey murine sarcoma
virus as an immunogen [22]. RAP-1 ~ 5 were generated
utilizing a synthetic H-p21Ras peptide reflecting amino
acid positions 10–17 with a mutation at codon 12 as the
immunogen [23]. RASK1 ~ 16 were generated using mu-
tated K-p21Ras from Kirsten murine sarcoma virus as the
immunogen [21].
Antibody genes can be fused into phage genes, and
then the antibodies can be expressed and displayed on
the surface of the phages as fusion proteins [40]. The
phage display library has thus become the most popular
technique for constructing and selecting scFv antibodies
from hybridomas or B lymphocytes due to its benefits,
such as the high diversity of the antigenic repertoire and
the ability to rapidly select specific antibodies [41]. In
this study, we employed the phage display library
method to isolate scFv antibodies against human p21Ras
proteins. Fortunately, we obtained scFv antibodies that
maintained all of the immunoreactivities of the original
monoclonal KGH-R1 antibodies, including the recogni-
tion of wildtype and mutated p21Ras proteins, reaction
with H-p21Ras, K-p21Ras and N-p21Ras, and strong im-
munostaining in tumour cell lines and primary tumours.
These results showed that scFv is useful for ras signal-
ling blockage and may be a therapeutic antibody for ras-
derived tumours.
The scFv antibodies presented here were dramatically
different from previous anti-p21Ras scFv in both their
nucleotide sequences and their amino acid sequences
[42, 43]. There was a 49.8 % difference from Y13-259
scFv and a 53.73 % difference from Y13-238 scFv, mostly
located in the CDRs (Fig. 3a). Our data indicated that
KGH-R1 scFv recognizes different antigen epitopes,
based on a comparison of Y13-259 scFv and Y13-238
scFv, and it is a novel anti-p21Ras scFv antibody.
Conclusions
In conclusion, this study presents a novel anti-p21Ras
scFv antibody, KGH-R1 scFv, produced by hybridoma and
phage scFv display library methods. Sequence analysis
showed that KGH-R1 scFv antibody has an approximately
Fig. 2 Preparation of anti p21Ras scFv. a Schematic diagram of scFv. The variable region of the heavy chain (VH) and the variable region of the
light chain (VL) were combined with a polypeptide linker. b Construction of scFv gene. The 340 bp VH fragment and 325 bp VL fragment were
amplified from the cDNA of the KGH-R1 hybridoma. This assembly reaction ultimately produces 750 bp of scFv. c The recombinant pCANTAB5E-scFv
plasmid was digested into two fragments by Sfi I and Not I: 750 bp of scFv and 4472 bp of pCANTAB-5E vector. d The phage-ELISA showed that after
three rounds of panning by H-p21Ras, K-p21Ras and N-p21Ras antigens, in turn, the number of output phages (unbound phages) was constant
at 1 × 106 PFU/ml, whereas the number of input phage was constant at 1 × 109 PFU/ml
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Fig. 3 Bioinformatics and immunoreactivity of the anti-p21Ras scFv. a Amino acid sequence of anti-p21Ras scFv with appropriate regions for
framework and CDR residues, differing from the previously reported Y13-159 scFv and Y13-238 scFv. b 3D model of anti-p21Ras scFv generated
by bioinformatics. Variable heavy chain (VH) and light chain (VL) regions of the antibody were connected by a single 15-amino acid linker (L, green).
c Western blot detected anti-p21Ras scFv antibody-specific binding with p21Ras protein in the cells, where strong immunoreactivity was found in
p21Ras-overexpressing tumour cell lines; however, weak immunoreactivity was observed in the normal cell line KMB17 with low p21Ras expression.
d Immunohistochemistry revealed that anti-p21Ras scFv antibody exhibited strongly positive staining in human tumour cell lines and primary solid
tumour tissues
Table 3 Immunoreactivity of KGHR1-scFv antibody in human tumour tissues and cell lines
Immunoreactivity (HSCOREsa) Immunocytochemistry
Tumour tissues Cases Primary tumour tissues Normal tissues Tumour cell lines Results
Colorectal cancer 30 180.54 ± 79.21 7.31 ± 2.13 BGC853 +
Gastric cancer 25 150.17 ± 64.31 7.13 ± 1.99 MKN28 +
Oesophageal cancer 25 151.42 ± 59.13 8.21 ± 2.38 HCT116 +
Bladder cancer 25 149.37 ± 79.27 7.23 ± 2.15 QGY7703 +
Lung adenocarcinoma 20 199.45 ± 69.11 8.13 ± 2.17 SMMC-7721 +
Lung squamous cell carcinoma 20 185.37 ± 71.64 7.53 ± 2.23 HepG2 +
Lung small cell carcinoma 19 146.25 ± 83.00 7.78 ± 2.17 MDA-MB-231 +
Papillary thyroid carcinoma 20 191.67 ± 82.71 7.93 ± 2.76 MDA-MB-435 +
Hepatocarcinoma 22 168.25 ± 79.33 8.47 ± 3.18 MCF7 +
Prostate carcinoma 25 145.37 ± 75.35 8.52 ± 3.43 HeLa +
Breast cancer 24 165.73 ± 63.28 7.93 ± 2.56 SKOV3 +
Endometrial cancer 30 153.32 ± 57.00 8.73 ± 3.63 Hep2 +
Glioma 20 131.50 ± 42.59 10.28 ± 5.00 T24 +
Renal cell carcinoma 24 89.61 ± 53.73 11.27 ± 4.91
aMean ± SD
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50 % difference from reported anti-p21Ras scFv anti-
bodies. The KGH-R1 scFv antibody could recognize
wildtype and mutated H-p21Ras, K-p21Ras, and N-p21Ras
and exhibited strong immunoreactivity with human tumour
cell lines and primary tumours. It is suggested that the scFv
may be useful for ras signalling blockage and as a thera-
peutic antibody for ras-derived tumours.
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